<DOC>
	<DOCNO>NCT00952822</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics safety Antihemophilic factor , recombinant , manufacture protein-free ( rAHF-PFM ) reconstitute 2 mL sterile water injection ( SWFI ) compare rAHF-PFM reconstitute 5 mL SWFI .</brief_summary>
	<brief_title>Pharmacokinetic Study ADVATE Reconstituted 2 mL Sterile Water Injection</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject subject 's legally authorize representative provide write informed consent The subject severe hemophilia A define baseline FVIII activity &lt; = 1 % normal ; test screen The adolescent/adult subject documented history least 150 exposure day FVIII concentrate ( either plasmaderived recombinant ) , pediatric subject least 50 exposure day The subject &gt; = 12 &lt; = 65 year age complete pharmacokinetic assessment &gt; = 2 &lt; 12 year incremental recovery assessment The subject Karnofsky performance score &gt; 60 The subject human immunodeficiency virus negative ( HIV ) HIV+ stable CD4 count &gt; = 200 cells/mmÂ³ ( CD4 count determine screening , necessary ) The subject know hypersensitivity mouse hamster proteins FVIII concentrate The subject history FVIII inhibitor titer &gt; = 0 . 5 BU ( Bethesda Assay ) &gt; = 0.4 BU ( Nijmegen modification Bethesda Assay ) time prior screen The subject detectable FVIII inhibitor screening , &gt; = 0.4 BU ( Nijmegen modification Bethesda Assay ) , central laboratory The subject severe chronic liver disease evidence , limited , follow : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varices The subject diagnose inherit acquire hemostatic defect hemophilia A ( e.g . qualitative platelet defect Von Willebrand Disease ) The subject receive another investigational product within 30 day enrollment The subject 's clinical condition may require major moderate surgery ( estimate blood loss &gt; 500 mL ) period participation study Subjects clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect subject safety compliance The subject female childbearing potential positive pregnancy test screening</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>